Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis
Article in Ocular Immunology and Inflammation (January 2024)
The most recent citing publications are shown below. View all 20 publications that cite this research output on Dimensions.
Article in Ocular Immunology and Inflammation (January 2024)
Article in Cancers (December 2022)
Article in Clinical Therapeutics (June 2022)